04.21.25 -- Top Bioprocessing Trends You Can't Afford to Miss

We know how tough it can be to find the right CDMO, especially when capacity is tight and timelines are critical. That's why we're bringing together 31 CDMOs for our Outsourced Pharma Capacity Update Partners Week — a chance to explore their latest capabilities and available capacity, all from the convenience of your screen. Learn more about our sessions grouped by modality to join us to find the right partner for your project.

Drug developers must understand the latest trends in microbial fermentation. By leveraging innovative methods and technologies, developers can unlock new opportunities and improve patient outcomes.

Capacity constraints typically are accompanied by other challenges, including missed timelines, defect rates, and overall decreased satisfaction with pharma companies’ bioprocessing CDMOs.

The potential advantages that stable bulk cultures can offer a drug development paradigm are poised to accelerate and bolster biopharmaceutical clinical manufacturing.

Recognizing the unexplored potential to save resources, one researcher realized consumption reduction of up to 50% during a key phase of downstream processing.

Partner with a CDMO that understands the unique challenges of emerging biopharma, providing expert guidance in formulation development, manufacturing, and regulatory navigation.

Explore how advanced machine learning and data analytics are revolutionizing biopharmaceutical manufacturing and driving operational excellence.

Unlocking the potential of next-generation therapeutics requires extending the boundaries of both expression system technology and process development and manufacturing.

Embrace the future of drug development by leveraging AI and innovative protein synthesis technologies to accelerate the creation of effective therapies and transform patient outcomes.

Technical transfers are one of the most critical, yet challenging steps in drug development; therefore, an effective strategy is essential to accelerate the translation of projects from bench to market.

CEO Cory Lewis explains how the company is adapting with rapid growth to deliver customizable and flexible solutions from early development support to commercial filling.

The ability to administer high doses of biologics subcutaneously offers numerous benefits, including reduced treatment burden, improved patient convenience, and increased treatment adherence.

Discover how CDMOs can help you achieve and maintain CMC compliance throughout the drug development lifecycle. Outsourced Pharma Live will explore how to leverage CDMO expertise in process optimization, documentation, and regulatory submissions. Learn practical strategies to align your CMC goals with CDMO capabilities to accelerate development and ensure successful drug launches.

Curia is now part of a powerful global network of 3,700+, with 29 global locations. Our integrated solutions and capabilities bridge discovery, engineering, development, and manufacturing across sites.

Partner with Mycenax for end-to-end ADC development and GMP manufacturing, turning your targeted therapy vision into reality with expert support from concept to clinic.

Developability, a key factor in a biologic's success, evaluates its manufacturability, safety, and efficacy. By proactively addressing concerns, we aim to enhance the likelihood of regulatory approval.

Xcellerex™ X-platform bioreactors deliver modular, scalable bioprocessing solutions with user-friendly features, optimized design, flexible automation, and efficient fluid management.